Alectinib approved by FDA for ALK-positive lung cancer Alectinib, a new drug for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer, has been approved by the US Food and Drug Administration.…
FDA approves uridine triacetate as chemotherapy overdose rescue A new rescue treatment for patients accidentally given an overdose of chemotherapy has been approved by the US Food and Drug Administration.…
Review of 2015: ten developments that are changing pharmacy The pharmacy landscape continues to shift amid a backdrop of austere UK public spending and the rising spectre of centralised dispensing in the community. The Pharmaceutical Journal presents ten developments that affected pharmacists in 2015.…
FDA approves ‘cooling cap’ to reduce hair loss during chemotherapy A cap that cools the scalp to reduce hair loss (alopecia) in women undergoing chemotherapy for breast cancer has been cleared for marketing by the US Food and Drug Administration.…
FDA approves treatment for inherited bleeding disorder Recombinant von Willebrand factor, a treatment for an inherited bleeding disorder, has been approved by the US Food and Drug Administration.…
Second clinical trial death puts the future of obesity drug in doubt The US Food and Drug Administration has given the pharmaceutical company Zafgen a verbal notice that its investigational new drug application for beloranib has been put on complete clinical hold after the death of a patient during a phase III clinical trial.…
FDA approves new multiple myeloma drug elotuzumab A new immune-stimulating treatment for multiple myeloma has been approved by the US Food and Drug Administration.…
FDA approves necitumumab for non-small cell lung cancer Necitumumab (Portrazza) has been approved by the US drugs safety watchdog as a new combination therapy for patients with advanced squamous non-small cell lung cancer who have not received other treatment for their advanced disease.…
Study supports cardiovascular safety of testosterone Despite FDA warnings, no link found between testosterone therapy and cardiovascular risks.…
FDA approves first oral proteasome inhibitor for multiple myeloma A new combination therapy for patients with multiple myeloma whose previous treatment has failed has been approved by the US Food and Drug Administration.…